Printer Friendly Printer Friendly   | Text Size Decrease Text Size Increase Text Size

Press Releases

Showing 1-35 of 334
First 1   2   3   4   5   6   7   8   9   10   Next   Last

2009
November

11/19/09 The Deal Names Abbott Top Dealmaker for Second Consecutive Year
11/17/09 Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform
11/16/09 Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
11/15/09 Abbott Statement on ARBITER 6 - HALTS Results and Abbott's Niaspan (niacin extended-release)
11/12/09 Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
11/12/09 New Web Sites Educate About Triglycerides and HDL Cholesterol
11/3/09 President of Tanzania and the Abbott Fund Dedicate Modern Emergency Medical Department
11/2/09 Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes
11/2/09 Abbott Completes Acquisition of Evalve, Inc.
11/2/09 Abbott Saving 1 Billion Gallons of Water Annually

October

10/29/09 Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
10/20/09 FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
10/20/09 Abbott Completes Visiogen Acquisition
10/19/09 ZonePerfect Indulgence™ Nutrition Squares Give Chocolate Lovers a Sensible Sweet-Tooth Option
10/14/09 Abbott Reports 16.5 Percent Earnings Growth in Third Quarter; Raises Earnings Guidance for 2009
10/6/09 Novel Abbott Test That Aids in the Early Diagnosis of Acute Kidney Injury (AKI) Receives CE Mark

September

9/30/09 Abbott Cuts Use of Oil and Coal by 35 Percent
9/28/09 Abbott to Acquire Solvay Pharmaceuticals Business
9/24/09 Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
9/24/09 Abbott Hosts Conference Call for Third-Quarter Earnings
9/23/09 Abbott's XIENCE V® Superior to TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Trial
9/23/09 Abbott's XIENCE V® Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS® Liberte in Investigator-Initiated COMPARE Trial
9/22/09 Abbott Again Honored for Offering One of the 'Top 10' Leading Workplaces
9/21/09 Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2
9/21/09 Abbott's XIENCE V® Continues to Outperform TAXUS with Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
9/17/09 Abbott Declares 343rd Consecutive Quarterly Dividend
9/16/09 Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts
9/16/09 Abbott Announces TCT 2009 Activities
9/15/09 Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
9/14/09 Abbott Announces Approval in China for Next-Generation XIENCE V® Drug Eluting Stent
9/14/09 Abbott Receives European Approval for Once-Daily Dosing of Kaletra® (lopinavir/ritonavir) Tablet
9/10/09 Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
9/4/09 Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek
9/3/09 Abbott Listed on Dow Jones Sustainability Indexes for Fifth Consecutive Year
9/2/09 Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
First 1   2   3   4   5   6   7   8   9   10   Next   Last

Narrow by Year

Narrow to Show

Survey

We would appreciate your feedback on our News and Media section. Please participate in our online survey.

Newsfeed

RSS

Subscribe to Abbott's Newsfeeds and get up-to-the-minute news from all of Abbott's businesses.


Home | Select a Country | Site Map | Contact Us | Privacy Policy | Terms of Use

Copyright © 2006, 2009 Abbott Laboratories. Abbott Park, Illinois, U.S.A.


Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.